English

• Kancera reports results from clinical Phase I study and strategy for continued development of KAND567

  20 February 2018

• Kancera reports that clinical Phase I study has been completed in the Fractalkine project

  20 December 2017

• Kancera acquires additional rights to the Fractalkine project

  11 December 2017

• Kancera performs the second partial payment for the Fractalkine project

  21 November 2017

• INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2017

  17 November 2017

• KANCERA PROVIDES AN OPERATIONAL UPDATE FOR THE ROR PROJECT

  4 October 2017

• Kancera and Recipharm collaborate to manufacture clinical trial supply

  14 September 2017

• Kancera announces start of  Phase 1 Multiple Ascending Dose Trial of KAND567

  11 September 2017

• INTERIM REPORT FOR KANCERA  AB (publ) JANUARI 1ST – JUNE 30TH 2017

  23 August 2017

• Kancera announces approval for the start of clinical trial of KAND567

  9 May 2017